- Home
- KRON vs UNCY Comparison
KRON vs UNCY Comparison
Compare KRON & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- UNCY
- Stock Information
- Founded
- KRON 2017
- UNCY 2016
- Country
- KRON United States
- UNCY United States
- Employees
- KRON N/A
- UNCY N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- UNCY Health Care
- Exchange
- KRON Nasdaq
- UNCY Nasdaq
- Market Cap
- KRON 59.1M
- UNCY 70.3M
- IPO Year
- KRON 2020
- UNCY 2021
- Fundamental
- Price
- KRON $0.99
- UNCY $0.62
- Analyst Decision
- KRON Buy
- UNCY Strong Buy
- Analyst Count
- KRON 3
- UNCY 4
- Target Price
- KRON $1.63
- UNCY $5.50
- AVG Volume (30 Days)
- KRON 292.4K
- UNCY 1.3M
- Earning Date
- KRON 11-13-2024
- UNCY 11-13-2024
- Dividend Yield
- KRON N/A
- UNCY N/A
- EPS Growth
- KRON N/A
- UNCY N/A
- EPS
- KRON N/A
- UNCY N/A
- Revenue
- KRON $9,864,000.00
- UNCY N/A
- Revenue This Year
- KRON $62.21
- UNCY N/A
- Revenue Next Year
- KRON N/A
- UNCY N/A
- P/E Ratio
- KRON N/A
- UNCY N/A
- Revenue Growth
- KRON 146.48
- UNCY N/A
- 52 Week Low
- KRON $0.69
- UNCY $0.20
- 52 Week High
- KRON $1.60
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- KRON 53.69
- UNCY 40.04
- Support Level
- KRON $0.92
- UNCY $0.61
- Resistance Level
- KRON $1.02
- UNCY $0.73
- Average True Range (ATR)
- KRON 0.05
- UNCY 0.07
- MACD
- KRON 0.00
- UNCY -0.02
- Stochastic Oscillator
- KRON 77.38
- UNCY 15.66
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.